



For Immediate Release

Symic Bio to Present at the 15th Annual BIO Investor Forum

SAN FRANCISCO, Oct. 11, 2016 – Symic Bio, a clinical stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology, today announced that Ken Horne, Chief Executive Officer, will present at the upcoming BIO Investor Forum conference.

Conference details:

Date: Tuesday, October 18, 2016

Time: 9:00 a.m. PDT

Location: Westin St. Francis Hotel, San Francisco

About Symic Bio

Symic Bio is a clinical stage biopharmaceutical company developing a new category of therapeutics focused on extracellular matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules of the extracellular matrix. Symic Bio currently has two clinical candidates, one for the treatment of critical limb ischemia (SB-030) and one directed at disease-modification in the treatment of osteoarthritis (SB-061). In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.

For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio/ or follow on Twitter at www.twitter.com/symicbio.

Media Contacts

David Schull or Rich Allan

Russo Partners, LLC

(212) 845-4271

(646) 942-5588

david.schull@russopartnersllc.com

rich.allan@russopartnersllc.com

###